Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 84-87

  Kushner, Brian H ^a   Kramer, Kim ^a   Modak, Shakeel ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DOXORUBICIN; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MESNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; NEUTRALIZING ANTIBODY; PLATINUM DERIVATIVE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPONATREMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROBLASTOMA; NEUTROPHIL; OUTCOMES RESEARCH; PRIORITY JOURNAL; TYPHLITIS; VOMITING;

ADOLESCENT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INFANT; MALE; MESNA; NEUROBLASTOMA; RETROSPECTIVE STUDIES; TOPOTECAN;

EID: 1642535499     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1147-3     Document Type: Article

References (35)

1. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
2. Zamboni, W. C., Stewart, C. F., Thompson, J., Santana, V. M., Cheshire, P. J., Richmond, L. B., Luo, X., Poquette, C., Houghton, J. A., and Houghton, P. J. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst. (Bethesda), 90: 505-511, 1998.
3. Komuro, H., Li, P., Tsuchida, Y., Yokomori, K., Nakajima, K., Aoyama, T., Kaneko, M., and Kaneda, N. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med. Pediatr. Oncol., 23: 487-492, 1994.
4. Vassal, G., Terrier-Lacombe, M. J., Bissery, M. C., Vénuat, A. M., Gyergyay, F., Bénard, J., Morizet, J., Boland, I., Ardouin, P., Bressac-de-Paillerets, B., et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br. J. Cancer, 74: 537-545, 1996.
5. Thompson. J., Zamboni. W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton. A., Stewart, C. F., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997.
6. Pratt, C. B., Stewart, C., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J. F., Heideman, R., Sandlund, J. T., et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12: 539-543, 1994.
7. Tubergen, D. G., Stewart, C. F., Pratt, C. B., Zamboni, W. C., Winick, N., Santana, V. M., Dryer, Z. A., Kurtzberg, J., Bell, B., Grier, H., et al. Phase 1 trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol., 18: 352-361. 1996.
8. Nitschke, R., Parkhurst, J., Sullivan, J., Harris, M. B., Bernstein, M., and Pratt, C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J. Pediatr. Hematol. Oncol., 20: 315-318, 1998.
9. Blaney, S. M., Balis, F. M., Cole, D. E., Craig, C., Reid, J. M., Ames, M. M., Krailo, M., Reaman, G., Hammond, D., and Poplack, D. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res., 53: 1032-1036, 1993.
10. Blaney, S. M., Needle, M. N., Gillespie, A., Sato, J. K., Reaman, G. H., Berg, S. L., Adamson, P. C., Krailo, M. D., Bleyer, W. A., Poplack, D. G., et al. Phase 11 trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group study. Clin. Cancer Res., 4: 357-360, 1998.
11. Kushner, B. H., Kramer, K., Meyers, P. A., Wollner, N., and Cheung, N-K. V. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med. Pediatr. Oncol. 35: 468-474, 2000.
12. Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffer, F. A., Meyer, W. H., et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J. Clin. Oncol., 17: 1815-1824, 1999.
13. Blaney, S., Berg, S., Pratt, C., Weitman, S., Sullivan, J., Luchtman-Jones, L., and Bernstein, M. A phase 1 study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin. Cancer Res., 7: 32-37, 2001.
14. Mugishima, H., Matsunaga, T., Keiko, Y., Asami, K., Mimaya, J., Suita, S., Kishimoto, T., Sawada, T., Tsuchida, Y., and Kaneko, M. Phase 1 study of irinotecan in pediatric patients with malignant solid tumors. J. Pediatr. Hematol. Oncol., 24: 94-100, 2002.
15. Cosetti, M., Wexler, L. H., Calleja, E., Trippett, T., LaQuaglia, M., Huvos, A. G., Gerald, W., Healey, J. H., Meyers, P. A., and Gorlick, R. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J. Pediatr. Hematol. Oncol., 24: 101-105, 2002.
16. Vassal, G., Doz, F., Frappaz, D., Gentet, J. C., Pichon, F., Chastagner, P., Rubie, H., Brennan, B., Pearson, A., Gerrard, M., et al. A phase II study of irinotecan (CPT -11) in children with relapsed or refractory neuroblastoma Med. Pediatr. Oncol. 39: 257, 2002.
17. Kretschmar, C., Kletzel, M., Murray, K., Joshi, V., Smith, E., Pao, P. V., and Castleberry, R. Upfront phase 11 therapy with taxol (Txl) and topotecan (topo) in untreated children (>35 days) with disseminated (INSS stage 4) neuroblastoma (NB). A Pediatric Oncology Group (POG) study. Med. Pediatr. Oncol. 25: 243, 1995.
18. Rosoff, P. M., and Bayliff, S. Successful clinical response to irinotecan in desmoplastic small round blue cell tumor. Med. Pediatr. Oncol., 33: 500-503, 1999.
19. Rodriguez-Galindo, C., Radomski, K., Stewart, C. F., Furman, W., Santana, V. M., and Houghton, P. J. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med. Pediatr. Oncol., 35: 385-402, 2000.
20. Saylors, R. L., Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bemstein, M. L., Harris, M. B., Hayashi, R., and Vietti, T. J. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J. Clin. Oncol., 19: 3463-3469, 2001.
21. Houghton, P. J., and Santana, V. M. Clinical trials using irinotecan. J. Pediatr. Hematol. Oncol., 24: 84-85, 2002.
22. Cheung, N-K. V., Cheung, I. Y., Canete, A., Yeh, S. J., Kushner, B., Bonilla, M. A., Heller, G., and Larson, S. M. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res., 54: 2228-2233, 1994.
23. D2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol., 16: 3053-3060, 1998.
24. D2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J. Clin. Oncol., 19: 4189-4194, 2001.
25. Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L. T., Castel, V., Castleberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., Hedborg, F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol., 11: 1466-1477, 1993.
26. Thompson, J., George, E. O., Poquette, C. A., Cheshire, P. J., Richmond, L. B., de Graaf, S. S. N., Ma, M., Stewart, C. F., and Houghton, P. J. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin. Cancer Res., 5: 3617-3631, 1999
27. Vietti, T., Crist, W., Ruby, E., Raney, B., Ruymann, F., Link, M., Grier, H., and Maurer, H. Topotecan window in patients with rhabdomyosarcoma: an IRSG study. Proc. Am. Soc. Clin. Oncol. 16: 510a, 1997.
28. Furman, W. L., Baker, S. D., Pratt, C. B., Rivera, G. K., Evans, W. E., and Stewart, C. F. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J. Clin. Oncol., 14: 1504-1511, 1996.
29. Ardizzoni, A., Hansen, H., Dombemowsky P., Gamucci, T., Kaplan, S., Postmus, P., Giaccone, G., Schaefer, B., Wanders, J., and Verweij, J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J. Clin. Oncol., 15: 2090-2096, 1997.
30. Rich, T. A., and Kirichenko, A. V. Camptothecin radiation sensitization: mechanisms, schedules, and timing. Oncology, 12: 114-120, 1998.
31. Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 52: 2268-2278, 1992.
32. Baker, S. D., Heideman, R. L., Crom, W. R., Kuttesch, J. F., Gajjar, A., and Stewart, C. F. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol., 37: 195-202, 1996.
33. Blaney, S. M., Takimoto, C., Murry, D. J., Kuttesch, N., McCully, C., Cole, D. E., Godwin, K., and Balis, F. M. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother. Pharmacol., 41: 464-468, 1998.
34. Saylors, R.L. III, Stewart, C. F., Zamboni, W. C., Wall, D. A., Bell, B., Stine, K. C., and Vietti, T. J. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group study. J. Clin. Oncol., 16: 945-952, 1998.
35. Murren, J. R., Anderson, S., Fedele, J., Pizzomo, G., Belliveau, D., Zelterman, D., Burtness, B. A., Tocino, I., Flynn, S. D., Beidler, D., et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J. Clin. Oncol., 15: 148-157, 1997.